Cancer Treatment Research
Active
- Assistance listing
- 93.395
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- 18,287 $28,262,839,486 in federal obligations
Program facts
- Assistance types
-
- Project Grant
- Cooperative Agreement
- Block Grant
- Treasury account
-
- 75-0849-0-1-550
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The Department of Health and Human Services National Institutes of Health funds cancer treatment research development and evaluation through CFDA 93.395, with the most recent grant award disbursed on September 3, 2026. The program supports discovery, development, and clinical testing of all therapeutic modalities—surgery, radiotherapy, chemotherapy, biological therapy including molecularly targeted therapies, stem cell and bone marrow transplantation, image-guided therapies, and supportive care methods that enhance primary treatment. Research spans fundamental and applied laboratory and clinical investigation to develop means to cure cancer patients and control disease in those not cured.
Grant awards remain highly active, with 391 awards in 2026 following 486 in 2024, 504 in 2023, and 515 in 2022—representing consistent annual funding around 400–500 awards. The program has sustained operations for over fifty years, with initial awards dating to October 1975. Combined federal dollars obligated total $28.26 billion across 18,287 awards; non-federal cost-share adds $1.36 billion for a combined total of $29.62 billion. The portfolio is dominated by the National Cancer Institute, which accounts for 5,502 awards and $20.5 billion in federal dollars—a 72% share of total federal funding. The broader NIH (non-NCI components) accounts for an additional 12,445 awards and $7.28 billion. Assistance-type distribution is heavily weighted toward Project Grants at 86% of the award count (15,734 awards), with Cooperative Agreements at 10% (1,744 awards) and Block Grants at 4% (809 awards).
Representative recent awards exemplify program scope: translation of oncolytic immunotherapy for colorectal cancer ($306,756); CAR-T cell therapy enhancement for diffuse large B-cell lymphoma ($548,528); cuproptosis-based approaches to chemoresistant ovarian cancer ($444,569); development of novel Wnt inhibitors for colorectal cancer through Phase I SBIR ($399,998); and AI-driven multi-omics integration for acute lymphoblastic leukemia categorization ($307,000). Award magnitudes typically range from $300 thousand to $700 thousand for standard R01/R21 projects, with larger Program Project ($2.7 million) and cooperative agreement awards occasionally exceeding $1 million.
Grant opportunities posted recently include the Investigator-Focused Award (Parent R35; PAR-28-037, posted July 30, 2026) to fund investigator programs with scientific freedom and funding stability; Advanced Development of Informatics Technologies for Cancer Research (RFA-CA-28-003, U24 Cooperative Agreement, posted July 28, 2026); and the Radiation Oncology-Biology Integration Network Centers (RFA-CA-27-003, U54 Cooperative Agreement, posted June 2, 2026). SBIR and STTR mechanisms remain active, with multiple small-business focused opportunities carrying due dates through 2029. The program exhibits no recent opportunities with near-term deadlines; most posted opportunities carry due dates of 2027 or later, suggesting opportunity posting activity remains steady but not urgent.
Objective and description
- Objective
To develop the means to cure as many cancer patients as possible and to control the disease in those patients who are not cured. Cancer Treatment Research includes the development and evaluation of improved methods of cancer treatment through the su
- Description
To develop the means to cure as many cancer patients as possible and to control the disease in those patients who are not cured. Cancer Treatment Research includes the development and evaluation of improved methods of cancer treatment through the support and performance of both fundamental and applied laboratory and clinical research. Research is supported in the discovery, development, and clinical testing of all modes of therapy including: surgery, radiotherapy, chemotherapy, and biological therapy including molecularly targeted therapies, both individually and in combination. In addition, research is carried out in areas of nutritional support, stem cell and bone marrow transplantation, image guided therapies and studies to reduce toxicity of cytotoxic therapies, and other methods of supportive care that may supplement and enhance primary treatment. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.
Eligibility
- Applicant eligibility
The awardee will be a university, college, hospital, public agency, nonprofit research institution, or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned, and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
- Beneficiary eligibility
Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.
- Uses of assistance
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. SBIR Phase I grants (of approximately 6-months duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.
- Length and time phasing of assistance
Grants and cooperative agreements: Average 3 to 4 years, maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funds are provided through Monthly Demand Payment System or an Electronic Transfer System. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.
How to apply
- Criteria for selecting proposals
The major elements in evaluating applications include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.
- Award procedure
Grant applications are evaluated by scientific authorities for scientific and technical merit. Applications must also be reviewed by the National Cancer Advisory Board. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance, consistent with NCI and NIH priorities and strategic plans. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533-2) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and if they are recommended for further consideration, by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.
- Time to approval or disapproval
Approximately 10 months. SBIR Applications: About 7-1/2 months.
- Renewals
Applications submitted for renewal are reviewed and selected for funding on a competitive basis.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/not97-232.html
Grant opportunities
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Grant awards
Latest 10 of 18,287 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | Public Health Institute | $1,091,691,391 | 4% |
| 2 | Dana-Farber Cancer Institute, Inc. | $831,026,911 | 3% |
| 3 | The Univeristy Of Texas M.d. Anderson Cancer Center | $768,811,311 | 3% |
| 4 | Icahn School Of Medicine At Mount Sinai | $755,506,852 | 3% |
| 5 | Brigham & Womens Hospital Inc. | $736,978,662 | 3% |
| 6 | Fred Hutchinson Cancer Center | $651,367,252 | 2% |
| 7 | Mayo Clinic | $590,552,711 | 2% |
| 8 | Sloan-Kettering Institute For Cancer Research | $587,920,728 | 2% |
| 9 | The Johns Hopkins University | $543,193,099 | 2% |
| 10 | NRG Oncology Foundation Inc. | $521,646,656 | 2% |
10 of 1,437 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $1,271,874,556 |
| FY2025 | $2,219,208,883 |
| FY2024 | $3,124,942,338 |
| FY2023 | $3,415,936,272 |
| FY2022 | $2,858,445,223 |
| FY2021 | $1,984,387,999 |
| FY2020 | $932,696,615 |
| FY2019 | $853,683,772 |
| FY2018 | $923,130,589 |
| FY2017 | $817,200,297 |
| FY2016 | $793,299,888 |
| FY2015 | $784,512,655 |
| FY2014 | $777,729,921 |
| FY2013 | $701,224,239 |
| FY2012 | $733,354,076 |
| FY2011 | $736,212,840 |
| FY2010 | $757,889,459 |
| FY2009 | $736,267,115 |
| FY2008 | $380,958,685 |
| FY2007 | $549,849,160 |
| FY2006 | $672,469,235 |
| FY2005 | $609,108,204 |
| FY2004 | $662,683,752 |
| FY2003 | $616,668,263 |
| FY2002 | $557,013,765 |
| FY2001 | $281,456,322 |
Show all 26
Quick answers
What is Assistance Listing 93.395?
Assistance Listing 93.395 is Cancer Treatment Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Cancer Treatment Research?
Its CFDA number is 93.395: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.395 awarded?
18,287 grant awards under 93.395 have obligated $28,262,839,486 in federal funds to 1,437 recipients.
Who receives the most funding from 93.395?
The recipients obligated the most under Cancer Treatment Research are Public Health Institute ($1,091,691,391), Dana-Farber Cancer Institute, Inc. ($831,026,911) and The Univeristy Of Texas M.d. Anderson Cancer Center ($768,811,311).
How much did 93.395 obligate in fiscal year 2025?
Grants under 93.395 obligated $2,219,208,883 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.395?
37 of the latest 50 opportunities under 93.395 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program